Ultragenyx Pharmaceutical Inc. (RARE)
NASDAQ: RARE · IEX Real-Time Price · USD
43.85
-0.43 (-0.97%)
Apr 25, 2024, 4:00 PM EDT - Market closed

Ultragenyx Pharmaceutical Income Statement

Millions USD. Fiscal year is Jan - Dec.
Year 2023202220212020201920182017201620152014 2013 - 2011
Revenue
434.25363.33351.41271.03103.7151.52.610.1300
Upgrade
Revenue Growth (YoY)
19.52%3.39%29.66%161.32%101.41%1871.48%1863.91%---
Upgrade
Cost of Revenue
45.2128.3216.016.139.011.150000
Upgrade
Gross Profit
389.04335.01335.4264.994.7150.352.610.1300
Upgrade
Selling, General & Admin
309.8278.14219.98182.93161.52127.7299.9164.943310.81
Upgrade
Research & Development
648.45705.79497.15412.08357.36294231.64183.2114.7445.97
Upgrade
Other Operating Expenses
0.341.571.690000000
Upgrade
Operating Expenses
958.59985.49718.82595.02518.88421.72331.55248.14147.7456.78
Upgrade
Operating Income
-569.55-650.49-383.42-330.12-424.17-371.37-328.94-248.01-147.74-56.78
Upgrade
Other Expense / Income
38.9251.2469.56-144.76-24.73-174.28-10.6-2.17-2.127.83
Upgrade
Pretax Income
-608.46-701.73-452.98-185.36-399.44-197.1-318.34-245.84-145.62-64.61
Upgrade
Income Tax
-1.835.71.041.213.280.51-16.20.0400
Upgrade
Net Income
-606.64-707.42-454.03-186.57-402.73-197.61-302.14-245.87-145.62-64.61
Upgrade
Shares Outstanding (Basic)
74706861575042403729
Upgrade
Shares Outstanding (Diluted)
74706861575042403729
Upgrade
Shares Change
5.19%3.13%11.42%7.54%13.66%17.25%7.24%7.62%27.91%750.14%
Upgrade
EPS (Basic)
-8.25-10.12-6.70-3.07-7.12-3.97-7.12-6.21-3.96-2.25
Upgrade
EPS (Diluted)
-8.25-10.12-6.70-3.07-7.12-3.97-7.12-6.21-3.96-2.25
Upgrade
Free Cash Flow
-519.07-496.59-411.79-176.13-370.22-294.64-256.64-171.16-110.93-46.78
Upgrade
Free Cash Flow Per Share
-7.06-7.10-6.07-2.90-6.54-5.92-6.04-4.32-3.02-1.63
Upgrade
Gross Margin
89.59%92.21%95.44%97.74%91.31%97.77%99.96%100.00%--
Upgrade
Operating Margin
-131.16%-179.03%-109.11%-121.80%-408.98%-721.18%-12593.49%-186471.43%--
Upgrade
Profit Margin
-139.70%-194.71%-129.20%-68.84%-388.31%-383.75%-11567.34%-184867.67%--
Upgrade
Free Cash Flow Margin
-119.53%-136.68%-117.18%-64.98%-356.96%-572.18%-9825.27%-128693.98%--
Upgrade
EBITDA
-582.46-683.51-439.74-173.1-390.91-177.56-312.51-242.42-144.23-63.93
Upgrade
EBITDA Margin
-134.13%-188.12%-125.14%-63.87%-376.91%-344.81%-11964.51%-182266.92%--
Upgrade
Depreciation & Amortization
26.0118.2213.2412.268.5419.545.833.421.380.68
Upgrade
EBIT
-608.46-701.73-452.98-185.36-399.44-197.1-318.34-245.84-145.62-64.61
Upgrade
EBIT Margin
-140.12%-193.14%-128.91%-68.39%-385.14%-382.75%-12187.52%-184841.35%--
Upgrade
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).